ORIGINAL ARTICLES

Expression and functional analysis of recombinant peptidyl-prolyl cis-trans isomerase gene of Babesia microti

  • SUN Jiahui ,
  • SONG Peng ,
  • CHEN Muxin ,
  • ZHOU Yan ,
  • LIN Lin ,
  • CHEN Jiaxu ,
  • CAI Yuchun
Expand
  • National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases; National Center for International Research on Tropical Diseases, Shanghai 200025, China

Received date: 2022-10-17

  Revised date: 2022-11-10

  Online published: 2022-12-27

Supported by

Shanghai Natural Science Foundation Fund(21ZR1469900);Shanghai Municipal Health Commission Fund(201940236);National Parasitic Resources Center, the Ministry of Science and Technology Fund(NPRC-2019-194-30)

Abstract

Objective To express the recombinant peptidyl-prolyl cis-trans isomerase gene of Babesia microti (BmPPIase) in prokaryotic cells and analyze its function. Methods BmPPIase information was screened and analyzed by bioinformatics. The target fragment BmPPIase was obtained via the total gene synthesis, to construct the recombinant plasmid pET28a-BmPPIase, which was then transfected into the competent cells of Escherichia coli BL21 for prokaryotic expression. The expressed recombinant protein was analyzed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and the protein was purified via nickel column affinity. The recombinant protein concentration was estimated based on the amount of bovine serum albumin (BSA) reference standard. New Zealand rabbits were immunized with the recombinant protein four times (1.5 mg dose each on the day 1, 15, 29, and 43) at multiple sites on their back to elicit antibodies. Carotid blood was collected on the day 53 after primary immunization, to examine specific polyclonal antibody titer using enzyme-linked immunosorbent assay (ELISA), and Western blotting was used to analyze the immunogenicity of the polyclonal antibody. Further, immunofluorescence assay was used to localize its distribution in B. microti. The suppressive effect of the protein was assayed by co-incubation with mice infected blood cells in vitro, and the experiment set recombinant BmPPIase groups (added the protein 500, 250, 100, 50, and 10 μg/ml at final concentration), splicing factor 1 group (unrelated protein control, added 500, 250, 100, 50, 10 μg/ml), BSA group (100 μg/ml), and blank control. After incubation for 48 h, the culture was stained with ethidium bromide, and the proportion of infected red blood cells was measured using flow cytometry to analyze the effect of the protein on the infection of B. microti to host red blood cells. Results Bioinformatics revealed that the BmPPIase was a cyclophilin type of PPIase and was homologous to the same protein in Babesia bovis, Theileria, Blastocystis hominis, and Plasmodium. As expected, the restriction enzyme digestion of the recombinant plasmid showed that the size of the inserted gene was 531 bp, which was validated using sequencing. SDS-PAGE showed that the recombinant protein BmPPIase was a soluble protein with a relative molecular weight of 19 000. After purification and elution, the protein concentration was 1.5 mg/ml. ELISA showed that the specific polyclonal antibody titer of the recombinant protein was > 1 : 80 000. In addition, Western blotting revealed that the polyclonal antibody could specifically recognize the recombinant protein, and the immunofluorescence localization assay showed that BmPPIase was distributed on the surface of the parasite as well as secreted. In vitro inhibition experiments showed that the rBmPPIase protein at different concentrations inhibited the infection of host cells to a certain level, the relative infection rate was (47.0 ± 1.2)% at 500 μg/ml. However, with the decrease of protein concentration, the inhibition effect of BmPPIase gradually weakened, the relative infection rate was (64.0 ± 0.3)% at 250 μg/ml, (78.0 ± 1.9)% at 100 μg/ml and (82.0 ± 0.25)% at 50 μg/ml respectively. The relative infection rate was (93.0 ± 0.22)% at 10 μg/ml with no significant effect. Conclusion The recombinant protein BmPPIase is a secretory protein distributed on the parasite surface, showing significant suppressive effect on B. microti infection of host cells in vitro.

Cite this article

SUN Jiahui , SONG Peng , CHEN Muxin , ZHOU Yan , LIN Lin , CHEN Jiaxu , CAI Yuchun . Expression and functional analysis of recombinant peptidyl-prolyl cis-trans isomerase gene of Babesia microti[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2023 , 41(1) : 29 -35 . DOI: 10.12140/j.issn.1000-7423.2023.01.005

References

[1] Vial HJ, Gorenflot A. Chemotherapy against babesiosis[J]. Vet Parasitol, 2006, 138(1/2): 147-160.
[2] Zhou X, Wang H, Xue JB, et al. Epidemic and research progress of babesiosis[J]. Chin J Schisto Control, 2019, 31(1): 63-70. (in Chinese)
  (周霞, 王慧, 薛靖波, 等. 国内外巴贝虫病流行现状与研究进展[J]. 中国血吸虫病防治杂志, 2019, 31(1): 63-70.)
[3] Schnittger L, Rodriguez AE, Florin-Christensen M, et al. Babesia: a world emerging[J]. Infect Genet Evol, 2012, 12(8):1788-1809.
[4] Goethert HK. What Babesia microti is now[J]. Pathogens, 2021, 10(9): 1168.
[5] Song P, Cai YC, Lu Y, et al. Establishment of mouse infection model of Babesia microti Lishui isolate and consequent pathological changes[J]. Chin J Parasitol Parasit Dis, 2022, 40(4): 493-499.. (in Chinese)
  (宋鹏, 蔡玉春, 卢艳, 等. 田鼠巴贝虫丽水分离株小鼠感染模型的建立及其病理变化[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(4): 493-499.)
[6] Yao LN, Ruan W, Zeng CY, et al. Pathogen identification and clinical diagnosis for one case infected with Babesia[J]. Chin J Parasitol Parasit Dis, 2012, 30(2): 118-121. (in Chinese)
  (姚立农, 阮卫, 曾长佑, 等. 1例人感染巴贝虫的诊断与病原体鉴定[J]. 中国寄生虫学与寄生虫病杂志, 2012, 30(2): 118-121.)
[7] Bloch EM, Kumar S, Krause PJ. Persistence of Babesia microti infection in humans[J]. Pathogens, 2019, 8(3): 102.
[8] Krause PJ. Human babesiosis[J]. Int J Parasitol, 2019, 49(2): 165-174.
[9] Wittner M, Rowin KS, Tanowitz HB, et al. Successful chemotherapy of transfusion babesiosis[J]. Ann Intern Med, 1982, 96(5): 601-604.
[10] Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis[J]. N Engl J Med, 2000, 343(20): 1454-1458.
[11] Yin M, Zhang HB, Tao Y, et al. Evaluation on the in vivo efficacy of malarone and atovaquoneazithromycin combination against Babesia microti in mice under different immune status[J]. Chin J Parasitol Parasit Dis, 2021, 39(5): 659-665, 673. (in Chinese)
  (殷梦, 张皓冰, 陶奕, 等. 马拉龙和阿托伐醌 + 阿奇霉素在不同免疫状态小鼠体内的抗田鼠巴贝虫药效评价[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(5): 659-665, 673.)
[12] Wormser GP, Prasad A, Neuhaus E, et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection[J]. Clin Infect Dis, 2010, 50(3): 381-386.
[13] Shaw PE. Peptidyl-prolyl cis/trans isomerases and transcription: is there a twist in the tail?[J]. EMBO Rep, 2007, 8(1): 40-45.
[14] Schiene-Fischer C. Multidomain peptidyl prolyl cis/trans isomerases[J]. Biochim Biophys Acta, 2015, 1850(10): 2005-2016.
[15] Solbach W, Forberg K, Kammerer E, et al. Suppressive effect of cyclosporin A on the development of Leishmania tropica-induced lesions in genetically susceptible BALB/c mice[J]. J Immunol, 1986, 137(2): 702-707.
[16] Bell A, Wernli B, Franklin RM. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin[J]. Biochem Pharmacol, 1994, 48(3): 495-503.
[17] Perrone AE, Milduberger N, Fuchs AG, et al. A functional analysis of the cyclophilin repertoire in the protozoan parasite Trypanosoma cruzi[J]. Biomolecules, 2018, 8(4): 132.
[18] Krause PJ, McKay K, Gadbaw J, et al. Increasing health burden of human babesiosis in endemic sites[J]. Am J Trop Med Hyg, 2003, 68(4): 431-436.
[19] Zhou X, Xia S, Huang JL, et al. Human babesiosis, an emerging tick-borne disease in the People’s Republic of China[J]. Parasit Vectors, 2014, 7(1): 509.
[20] Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2006, 43(9): 1089-1134.
[21] Sanchez E, Vannier E, Wormser GP, et al. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review[J]. JAMA, 2016, 315(16): 1767-1777.
[22] Harikishore A, Yoon HS. Immunophilins: structures, mechanisms and ligands[J]. Curr Mol Pharmacol, 2015, 9(1): 37-47.
[23] Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes[J]. Cell, 1991, 66(4): 807-815.
[24] Gavigan CS, Kiely SP, Hirtzlin J, et al. Cyclosporin-binding proteins of Plasmodium falciparum[J]. Int J Parasitol, 2003, 33(9): 987-996.
[25] Ibrahim HM, Xuan XN, Nishikawa Y. Toxoplasma gondii cyclophilin 18 regulates the proliferation and migration of murine macrophages and spleen cells[J]. Clin Vaccine Immunol, 2010, 17(9): 1322-1329.
[26] Guo ZY, Jing CX, Huang XY, et al. The bioinformatic analysis of CyPs from Cryptosporidium parvum[J]. J Trop Med, 2018, 18(10): 1263-1269. (in Chinese)
  (郭志云, 荆春霞, 黄小英, 等. 微小隐孢子虫CyPs家族蛋白的生物信息学分析[J]. 热带医学杂志, 2018, 18(10): 1263-1269.)
[27] Potenza M, Galat A, Minning TA, et al. Analysis of the Trypanosoma cruzi cyclophilin gene family and identification of Cyclosporin A binding proteins[J]. Parasitology, 2006, 132(Pt 6): 867-882.
[28] Krücken J, Greif G, von Samson-Himmelstjerna G. In silico analysis of the cyclophilin repertoire of apicomplexan parasites[J]. Parasit Vectors, 2009, 2(1): 27.
[29] Deng WW, Wang L, Xiong Y, et al. The novel secretory protein CGREF1 inhibits the activation of AP-1 transcriptional activity and cell proliferation[J]. Int J Biochem Cell Biol, 2015, 65: 32-39.
[30] Liao YT, Luo D, Peng KL, et al. Cyclophilin A: a key player for etiological agent infection[J]. Appl Microbiol Biotechnol, 2021, 105(4): 1365-1377.
[31] Zhang Y, Jiang N, Lu HJ, et al. Proteomic analysis of Plasmodium falciparum schizonts reveals heparin-binding merozoite proteins[J]. J Proteome Res, 2013, 12(5): 2185-2193.
Outlines

/

〈 〉